Disease Overview：Gastric neuroendocrine tumor（GNET）
Gastric neuroendocrine tumors (gNETs) are rare, heterogeneous neoplasms arising from enterochromaffin-like (ECL) cells in the gastric mucosa. Classified under gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), gNETs are graded (G1–G3) and staged (AJCC/UICC TNM) based on mitotic rate, Ki-67 index, tumor size, depth of invasion, lymph node involvement, and distant metastasis. Type I (associated with chronic atrophic gastritis and hypergastrinemia) is most common and typically indolent; Type II (linked to Zollinger-Ellison syndrome) and Type III (sporadic, non-gastrin-driven) carry higher malignant potential. Diagnosis relies on high-definition endoscopy with targeted biopsies, somatostatin receptor imaging (e.g., ⁶⁸Ga-DOTATATE PET/CT), and histopathological confirmation with immunohistochemistry (chromogranin A, synaptophysin, Ki-67). Management is multidisciplinary—ranging from endoscopic resection for small, localized G1/G2 lesions to surgical gastrectomy, peptide receptor radionuclide therapy (PRRT), or systemic agents (everolimus, sunitinib) for advanced disease.
China offers distinct advantages for gNET management: leading academic hospitals—such as Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center—host dedicated neuroendocrine tumor boards with internationally trained gastroenterologists, oncologists, and nuclear medicine specialists. Advanced capabilities include AI-enhanced endoscopic detection, real-time confocal laser endomicroscopy, and access to FDA- and NMPA-approved therapeutics—including PRRT and novel targeted agents—often at 40–60% lower costs than in the US or Western Europe, without compromising clinical outcomes. Published cohort studies report 5-year overall survival rates exceeding 90% for localized gNETs treated in top-tier Chinese centers.
As a specialized medical tourism agency, we facilitate seamless care for international patients: coordinating appointments with certified gNET experts, verifying hospital credentials, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and multilingual clinical liaison—all tailored to individual diagnostic and therapeutic needs.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Gastric Neuroendocrine Tumors (gNETs)
Non-Surgical / Conservative / Medical Management
*Indicated for Grade 1/2 gNETs <2 cm, multifocal type I (associated with chronic atrophic gastritis), or asymptomatic low-grade tumors.*
- •Somatostatin Analogues (Octreotide LAR or Lanreotide)
- *Cost (per dose):* $480–$620 (30 mg octreotide LAR; 120 mg lanreotide)
- •Proton Pump Inhibitors (PPIs)
- *Cost (30-day supply):* $12–$22 (esomeprazole 40 mg OD)
- •Endoscopic Surveillance
- *Itemized Fees:* - Gastroscopy + targeted biopsy: $185–$240 - Chromoendoscopy (indigo carmine): $45–$65 - Pathology (H&E + synaptophysin/chromogranin IHC): $110–$155
Surgical / Procedural / Interventional Options
*Indicated for type III gNETs, type II with Zollinger-Ellison syndrome, type I >2 cm or progressive, or any gNET with lymph node involvement.*
- •Endoscopic Resection (ESD/EMR)
- *Procedure Cost:* $2,100–$3,400 - *Pre-op Workup:* EUS ($320–$410), CT abdomen ($270–$350), serum chromogranin A ($45–$65)
- •Laparoscopic/Robotic Gastrectomy
- *Procedure Cost:* $5,900–$8,600 (subtotal gastrectomy); $7,200–$9,800 (total gastrectomy) - *Pre-op Workup:* EUS ($320–$410), CT chest/abdomen/pelvis ($410–$530), OctreoScan/SSTR-PET ($1,150–$1,480)
Special / Complex Condition Options
- •Liver-Directed Therapy (TACE/TAE)
- *Cost per session:* $3,800–$5,200
- •Peptide Receptor Radionuclide Therapy (PRRT)
- *Cost (4-cycle course):* $22,500–$28,700 (¹⁷⁷Lu-DOTATATE)
Quick Selection Guide
- •<60 years, fit, single 1.8 cm type I gNET: Endoscopic resection ($2,100–$3,400) + lifelong PPI + surveillance
- •>75 years, multiple comorbidities, asymptomatic type I: Conservative management (PPI + annual endoscopy; $250/year)
- •Type III, 3.2 cm, no metastases: Laparoscopic subtotal gastrectomy ($5,900–$8,600) + full staging workup
- •Young patient, liver mets, SSTR-positive: PRRT ($22,500–$28,700) after confirming eligibility via SSTR-PET
- •Budget-constrained (<$3,000), symptomatic grade 1: Octreotide LAR ($480/dose × 4 doses/year = $1,920) + surveillance endoscopy ($185–$240)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Gastric neuroendocrine tumor Medical Vacation Packages
Curated transparent all-inclusive packages combining Gastric neuroendocrine tumor treatment with China top medical destinations:
